Klinische studies chronisch lymfatische leukemie (CLL)

Onbehandelde patiënten

LOXO BTX-20030

A phase 3 open label randomized study of pirtobrutinib versus Ibrutinib in patients with CLL / SLL: PART 2 evaluates pirtobrutinib mono in treatment naïve CLL/SLL with 17p deletions

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT05254743
• Internal reference number: S66576

BELLWAVE-011 (MK1026-011-00)

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06136559
• Internal reference number: S68241

Behandelde patiënten

HOVON 159

A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)

• Principal investigator: Prof. Dr. Ann Janssens
• More information: HOVON 159
• Internal reference number: S64626

MALT1 (M23-324)

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT05618028
• Internal reference number: S67551

J2N-MC-JZNX

A phase 2, open label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who previously received treatment with a covalent bruton tyrosine kinase inhibitor.

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06588478
• Internal reference number: S69650

GLORA (APG2575CG301)

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06104566
• Internal reference number: S68713